Evotec SE — Regulatory Filings 2012

Jul 10, 2012

News Details

Corporate | 10 July 2012 07:12

Evotec AG: CureBeta, a collaboration between Evotec and Harvard University enters strategic alliance with Janssen Pharmaceuticals

Evotec AG / Key word(s): Contract

10.07.2012 / 07:12

---

Hamburg, Germany - 10 July 2012: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has licensed to Janssen Pharmaceuticals,
Inc. a portfolio of small molecules and biologics designed to trigger the
regeneration of insulin-producing beta cells.

Under the terms of this license and collaboration agreement, Janssen will
receive exclusive access to a series of candidates designed to trigger the
regeneration of insulin-producing beta cells. The small molecules and
biologics were identified by scientists in the Harvard University
laboratory of Douglas Melton, and further analyzed in collaboration with
scientists from Evotec, as part of the CureBeta research and development
program.

The agreement between Evotec and Janssen triggers an upfront payment of US
$8 million. Upon achievement of certain pre-clinical, clinical, regulatory
and commercial goals, Janssen would make future milestone payments, of up
to a total of about US $200 million to US $300 million per product. In
addition, Janssen will pay royalties on future sales of any products that
result from this collaboration. The upfront, milestone and royalty payments
will be shared by Evotec and Harvard according to pre-agreed terms. Evotec
will receive additional research support for discovery and early
development work that will be conducted in collaboration with Janssen.

The CureBeta initiative was established by Harvard, the Howard Hughes
Medical Institute (HHMI), and Evotec in 2011 to leverage the assets and
expertise in industry and academia to identify and develop disease-state
modifying therapeutic targets. To that end, Evotec's Dr. Cord Dohrmann and
Harvard University Professor and Howard Hughes Medical Institute
Investigator Doug Melton, recognized leaders in the field of beta cell
research, began a unique international collaboration. During the initial
period of the collaboration, Evotec, HHMI, and Harvard established new
standards in beta cell regeneration in terms of assays and tools as well as
novel high potential targets. Janssen Pharmaceuticals will provide
industrial scope and scale as well as pharmaceutical development expertise
and marketing capabilities.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, commented: 'Our
collaboration with Doug Melton's laboratory has been extremely successful
on multiple levels. We have not only achieved our scientific goals of
creating a superior beta cell drug discovery platform and generating a deep
pipeline of novel and exciting targets, but we have also established a new
model of collaboration between academia and industry that has proven highly
efficient and effective in accelerating innovative scientific development.
Janssen Pharmaceuticals perfectly complements this effort, bringing in
world-leading pharmaceutical development expertise as well as the necessary
resources to execute on our mission to produce first-in-class therapeutics
designed to restore beta cell mass and function.'

'Our collaboration with Evotec supports our mission of accelerating
scientific research from the lab to the clinic,' said Isaac T. Kohlberg,
Harvard's chief technology development officer and head of its Office of
Technology Development. 'As the funding and licensing landscape has evolved
in the pharmaceutical industry, we have evolved to identify new development
strategies for our research assets. This alliance with Janssen
Pharmaceuticals represents an important step towards a real solution for
the treatment of diabetes.'

Juvenile Diabetes Research Foundation (JDRF) comments from Dr. Richard
Insel, Chief Scientific Officer: 'We are delighted to see Evotec, Dr. Doug
Melton, and Janssen launch this collaborative partnership and commitment to
develop innovative regenerative medicine therapies for diabetes. JDRF has
been actively supporting research in the field of beta cell regenerative
therapies, including other collaborative partnering programs with Evotec
and Janssen Pharmaceuticals. JDRF looks forward to supporting the CureBeta
initiative.'

Evotec invites you to join a conference call announcing the license
agreement to Janssen Pharmaceuticals

Details of the Conference Call:

10, July 2012 at

3.00 p.m. CET
2.00 p.m. BST
6.00 a.m. PDT / 9.00 a.m. EDT

Dial-in Numbers:

Europe:
+49 (0) 6103 485 3001 (Germany)
+44-207-153-2027 (UK)
+1-480-629-9673 (US)

Pass Code: 4548676

A simultaneous slide presentation for participants dialing in via phone is
available at www.equitystory.com, password:
evotec0712. You can also listen to the conference call via audio webcast
including presentation slides at www.evotec.com.

If you are unable to attend, a recording will be available for 24 hours
after the call at the following phone numbers: +49 69 58 99 90 567
(Germany), +44 20 7959 6720 (UK), +1 303 590 3030 (US). The access code is
4548676#. The on-demand version of the webcast will be available on our
website: http://www.evotec.com - Investors/Events/Financial Calendar.

Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
werner.lanthaler@evotec.com

FORWARD LOOKING STATEMENTS - Information set forth in this press
release contains forward-looking statements, which involve a number of
risks and uncertainties. The forward-looking statements contained herein
represent the judgement of Evotec as of the date of this report. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.

End of Corporate News

---

10.07.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart

End of News DGAP News-Service

177219 10.07.2012